| Gene symbol | CBLB | Synonyms | ADMIO3, Cbl-b, Nbla00127, RNF56 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q13.11 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | Cbl proto-oncogene B | ||||
| Gene symbol | DCX | Synonyms | DBCN, DC, LISX, SCLH, XLIS | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq23 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | doublecortin | ||||
| GTO ID | GTC1484 |
| Trial ID | NCT02166255 |
| Disease | Pancreatic Cancer | Renal Cell Carcinoma | Melanoma |
| Altered gene | Cbl-b|DC |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | APN401 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401 |
| Year | 2014 |
| Country | United States |
| Company sponsor | Wake Forest University Health Sciences |
| Other ID(s) | IRB00027911|NCI-2014-01234|CCCWFU 99114|P30CA012197 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||